These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 12730350)

  • 1. LY503430, a novel alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor potentiator with functional, neuroprotective and neurotrophic effects in rodent models of Parkinson's disease.
    Murray TK; Whalley K; Robinson CS; Ward MA; Hicks CA; Lodge D; Vandergriff JL; Baumbarger P; Siuda E; Gates M; Ogden AM; Skolnick P; Zimmerman DM; Nisenbaum ES; Bleakman D; O'Neill MJ
    J Pharmacol Exp Ther; 2003 Aug; 306(2):752-62. PubMed ID: 12730350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurotrophic actions of the novel AMPA receptor potentiator, LY404187, in rodent models of Parkinson's disease.
    O'Neill MJ; Murray TK; Whalley K; Ward MA; Hicks CA; Woodhouse S; Osborne DJ; Skolnick P
    Eur J Pharmacol; 2004 Feb; 486(2):163-74. PubMed ID: 14975705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LY503430: pharmacology, pharmacokinetics, and effects in rodent models of Parkinson's disease.
    O'Neill MJ; Murray TK; Clay MP; Lindstrom T; Yang CR; Nisenbaum ES
    CNS Drug Rev; 2005; 11(1):77-96. PubMed ID: 15867954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator.
    Baumbarger PJ; Muhlhauser M; Zhai J; Yang CR; Nisenbaum ES
    J Pharmacol Exp Ther; 2001 Jul; 298(1):86-102. PubMed ID: 11408529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological characterization of cGMP regulation by the biarylpropylsulfonamide class of positive, allosteric modulators of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors.
    Ryder JW; Falcone JF; Manro JR; Svensson KA; Merchant KM
    J Pharmacol Exp Ther; 2006 Oct; 319(1):293-8. PubMed ID: 16803862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPD 502: a water-soluble and in vivo long-lasting AMPA antagonist with neuroprotective activity.
    Nielsen EO; Varming T; Mathiesen C; Jensen LH; Moller A; Gouliaev AH; Wätjen F; Drejer J
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1492-501. PubMed ID: 10336544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AMPA receptor potentiators for the treatment of CNS disorders.
    O'Neill MJ; Bleakman D; Zimmerman DM; Nisenbaum ES
    Curr Drug Targets CNS Neurol Disord; 2004 Jun; 3(3):181-94. PubMed ID: 15180479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Granulocyte-colony stimulating factor is neuroprotective in a model of Parkinson's disease.
    Meuer K; Pitzer C; Teismann P; Krüger C; Göricke B; Laage R; Lingor P; Peters K; Schlachetzki JC; Kobayashi K; Dietz GP; Weber D; Ferger B; Schäbitz WR; Bach A; Schulz JB; Bähr M; Schneider A; Weishaupt JH
    J Neurochem; 2006 May; 97(3):675-86. PubMed ID: 16573658
    [TBL] [Abstract][Full Text] [Related]  

  • 9. GAP-43 is essential for the neurotrophic effects of BDNF and positive AMPA receptor modulator S18986.
    Gupta SK; Mishra R; Kusum S; Spedding M; Meiri KF; Gressens P; Mani S
    Cell Death Differ; 2009 Apr; 16(4):624-37. PubMed ID: 19136940
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
    Bustos G; Abarca J; Bustos V; Riquelme E; Noriega V; Moya C; Campusano J
    J Neurosci Res; 2009 Aug; 87(10):2308-18. PubMed ID: 19326433
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protective effects of Chunghyuldan against ROS-mediated neuronal cell death in models of Parkinson's disease.
    Kim HG; Ju MS; Kim DH; Hong J; Cho SH; Cho KH; Park W; Lee EH; Kim SY; Oh MS
    Basic Clin Pharmacol Toxicol; 2010 Dec; 107(6):958-64. PubMed ID: 20629656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a memory-enhancing drug on DL-alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor currents and synaptic transmission in hippocampus.
    Arai A; Kessler M; Rogers G; Lynch G
    J Pharmacol Exp Ther; 1996 Aug; 278(2):627-38. PubMed ID: 8768713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMPA receptor-mediated cell death is reduced by docosahexaenoic acid but not by eicosapentaenoic acid in area CA1 of hippocampal slice cultures.
    Ménard C; Patenaude C; Gagné AM; Massicotte G
    J Neurosci Res; 2009 Mar; 87(4):876-86. PubMed ID: 18951489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ampakine CX546 bolsters energetic response of astrocytes: a novel target for cognitive-enhancing drugs acting as alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor modulators.
    Pellerin L; Magistretti PJ
    J Neurochem; 2005 Feb; 92(3):668-77. PubMed ID: 15659236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rotenone potentiates NMDA currents in substantia nigra dopamine neurons.
    Wu YN; Johnson SW
    Neurosci Lett; 2007 Jun; 421(2):96-100. PubMed ID: 17560718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heteroaryl analogues of AMPA. 2. Synthesis, absolute stereochemistry, photochemistry, and structure-activity relationships.
    Falch E; Brehm L; Mikkelsen I; Johansen TN; Skjaerbaek N; Nielsen B; Stensbøl TB; Ebert B; Krogsgaard-Larsen P
    J Med Chem; 1998 Jul; 41(14):2513-23. PubMed ID: 9651156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of somatostatin receptor (sst 5) protects the rat retina from AMPA-induced neurotoxicity.
    Kiagiadaki F; Savvaki M; Thermos K
    Neuropharmacology; 2010 Jan; 58(1):297-303. PubMed ID: 19576912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential regulation of the expression of nerve growth factor, brain-derived neurotrophic factor, and neurotrophin-3 after excitotoxicity in a rat model of Huntington's disease.
    Canals JM; Marco S; Checa N; Michels A; Pérez-Navarro E; Arenas E; Alberch J
    Neurobiol Dis; 1998 Nov; 5(5):357-64. PubMed ID: 10069578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroprotective effects of metabotropic glutamate receptor ligands in a 6-hydroxydopamine rodent model of Parkinson's disease.
    Vernon AC; Palmer S; Datla KP; Zbarsky V; Croucher MJ; Dexter DT
    Eur J Neurosci; 2005 Oct; 22(7):1799-806. PubMed ID: 16197521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.